Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Barchart on MSN2d
Gilead Sciences’ Quarterly Earnings Preview: What You Need to KnowGilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
An Antidiabetic Helps the Immune System Recognize Reservoirs of HIV Sep. 10, 2024 — Metformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it ...
Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback